Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Propose...(MSD achieved 2007 full-year sales of eur...),Health

(5) Internal estimate

Net sales by geographic region

Change on a Change on a

Q4 2007 comparable FY 2007 comparable

euro million net sales basis net sales basis

Europe 3,056 -0.4% 12,184 -0.4%

United States 2,181 -8.5% 9,474 +3.8%

Other Countries 1,674 +3.8% 6,394 +7.8%

TOTAL 6,911 -2.2% 28,052 +2.8%

Net sales fell slightly in Europe in the fourth quarter, mainly as a result of the continuing decline in net sales in Germany. Over 2007 as a whole, net sales were down by 0.4%, with the introduction of generics of Eloxatin(R) paring approximately 1.6% off growth for the period.

In the United States, fourth-quarter net sales were down 8.5%, affected by generics of Ambien(R) IR (which went off patent on April 20) and lower influenza vaccine sales (a substantial proportion of shipments having been postponed to the fourth quarter in 2006, making for a tough comparative). Excluding the effect of generics of Ambien(R) IR and of timing differences in shipments of vaccines, net sales growth in the United States would have been 14.4%. Over 2007 as a whole, net sales rose by 3.8%. After excluding the effect of generics of Ambien(R) IR from April 2007, net sales in the United States rose by 15.1%.

Fourth-quarter net sales in "Other Countries" increased by 3.8%, below the full-year growth rate. Excluding the effect of the repurchase of inventories from Astellas and Chugai following the signature of agreements with these two companies on
'/>"/>